ARNAS Civico Di Cristina Benfratelli
- Address
- lock Available on a paid plan
Neurology and Neuroimmunology
At ARNAS Civico Di Cristina Benfratelli, clinical trials in multiple sclerosis, generalized myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy focus on improving symptom control, slowing disease activity, and testing new treatment options for immune-related nervous system disorders.
- Relapsing and progressive forms of multiple sclerosis
- Myasthenia gravis and daily function outcomes
- Inflammatory neuropathies such as CIDP
These studies aim to evaluate whether newer therapies can better reduce disability and preserve quality of life in patients with chronic neurologic disease.
Hematology and Pediatric Oncology
The site has a strong research profile in acute lymphoblastic leukemia, lymphoblastic lymphoma, neuroblastoma, rhabdomyosarcoma, and other childhood cancers, with trials designed to improve survival and reduce relapse risk.
- Acute lymphoblastic leukemia in children, adolescents, and relapsed disease
- Lymphoblastic lymphoma and related blood cancers
- Neuroblastoma, rhabdomyosarcoma, and osteosarcoma
Research at this hospital includes testing more effective treatment combinations and refining care for high-risk or relapsed cancers.
Cardiovascular and Metabolic Diseases
Clinical trials in cardiovascular disease, heart failure, hypertension, and type 2 diabetes are exploring ways to lower major cardiac risks and improve long-term disease control.
- Heart failure and prevention of worsening disease
- Atherosclerotic cardiovascular disease and systemic inflammation
- Type 2 diabetes with high cardiovascular risk
These studies are aimed at finding better strategies to prevent complications and support patients living with complex cardiometabolic conditions.
Oncology and Precision Cancer Medicine
Research in solid tumors at ARNAS Civico Di Cristina Benfratelli includes trials in colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, and urothelial cancer, often with a focus on targeted and personalized treatment approaches.
- Metastatic colorectal cancer and molecularly selected subgroups
- Prostate cancer, including advanced and high-risk disease
- Ovarian, pancreatic, and urothelial cancers
The main goal is to evaluate whether tailored therapies can improve response, delay progression, and offer better outcomes than standard treatment alone.
Rheumatology, Immunology, and Inflammatory Conditions
Trials in juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, recurrent pericarditis, and other immune-mediated disorders are studying how to better control inflammation and prevent flares.
- Juvenile idiopathic arthritis and treatment strategies in children
- Systemic juvenile idiopathic arthritis and targeted therapy
- Recurrent pericarditis and steroid-sparing approaches
These studies seek safer and more effective options for patients who do not respond well to standard anti-inflammatory care.
Kidney, Digestive, and Other Specialized Clinical Research
The site also supports trials in IgA nephropathy, endometriosis, digestive system diseases, and other conditions, showing a broad interest in both chronic disease management and symptom relief.
- IgA nephropathy and kidney protection
- Endometriosis and pain-related outcomes
- Metabolic and immune-mediated conditions with unmet treatment needs
These studies are designed to improve diagnosis, reduce disease burden, and test therapies that may offer better control with fewer side effects.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 124 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 111 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 30 by active trials.
lock +29 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ARNAS Civico Di Cristina Benfratelli
lock Showing 1 of 47 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | Janssen Cilag International | Phase III | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 124 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 8 | Unknown | 2018-07-15 | 2024-12-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.